12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sativex regulatory update

Germany's Federal Joint Committee (G-BA) said Sativex from GW Pharmaceuticals provides a "marginal" degree of additional benefit over optimized standard therapy to treat spasticity in multiple sclerosis (MS) patients. In April, the Institute for Quality and Efficiency in Health Care (IQWiG) issued a preliminary assessment that found no additional benefit for the...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >